These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 9825802)

  • 1. Hepatitis A antibody prevalence among young adults in Israel--the decline continues.
    Gdalevich M; Grotto I; Mandel Y; Mimouni D; Shemer J; Ashkenazi I
    Epidemiol Infect; 1998 Oct; 121(2):477-9. PubMed ID: 9825802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sociodemographic factors and the declining prevalence of anti-hepatitis A antibodies in young adults in Israel: implications for the new hepatitis A vaccines.
    Green MS; Tsur S; Slepon R
    Int J Epidemiol; 1992 Feb; 21(1):136-41. PubMed ID: 1544745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Seroepidemiology of hepatitis A virus infection in medical and nursing students. The role of vaccination].
    Buti M; Campins M; Jardí R; Navas E; Cotrina M; Llobet E; Vaqué J; Esteban R
    Gastroenterol Hepatol; 1996 Apr; 19(4):199-202. PubMed ID: 8665357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current seroepidemiological status of hepatitis A with a comparison of antibody titers after infection and vaccination.
    Fujiyama S; Odoh K; Kuramoto I; Mizuno K; Tsurusaki R; Sato T
    J Hepatol; 1994 Oct; 21(4):641-5. PubMed ID: 7814811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction in hepatitis A antibody prevalence among young adults in Israel.
    Kark JD; Camhy NA; Shany SB
    Public Health Rev; 1992-1993; 20(1-2):31-40. PubMed ID: 1305975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population seroprotection against hepatitis a virus in Israel 18 years after introduction of inactivated vaccine into the routine childhood vaccination schedule.
    Galor I; Perry Markovich M; Wolf D; Haber M; Hartal M; Avramovich E
    Vaccine; 2020 Feb; 38(7):1593-1596. PubMed ID: 31932135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis A infection: a seroepidemiological study in young adults in North-East Italy.
    Moschen ME; Floreani A; Zamparo E; Baldo V; Majori S; Gasparini V; Trivello R
    Eur J Epidemiol; 1997 Dec; 13(8):875-8. PubMed ID: 9476815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prevalence of hepatitis A antibodies among Israeli travellers and the economic feasibility of screening before vaccination.
    Schwartz E; Raveh D
    Int J Epidemiol; 1998 Feb; 27(1):118-20. PubMed ID: 9563704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of universal toddlers-only hepatitis A virus vaccination program on seropositivity rate in unvaccinated toddlers: evidence for reduced virus circulation in the community.
    Barkai G; Belmaker I; Givon-Lavi N; Dagan R
    Pediatr Infect Dis J; 2009 May; 28(5):391-3. PubMed ID: 19295466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and reactogenicity of an inactivated hepatitis A vaccine in Indian adults.
    Das K; Jain A; Gupta RK; Kar P
    Natl Med J India; 1999; 12(6):268-9. PubMed ID: 10732428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Active versus passive immunization against hepatitis A in the Israel defence forces: a cost-benefit analysis.
    Gillis D; Yetiv N; Gdalevich M; Mimouni D; Ashkenazi I; Shpilberg O; Eldad A; Shemer J
    Vaccine; 2000 Jul; 18(26):3005-10. PubMed ID: 10825603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Seroprevalence of anti-hepatitis A antibodies in Czech soldiers serving in U.N. forces--suggestions for a hepatitis A vaccination schedule].
    Beran J; Douda P; Prymula R; Splino M; Gál P; Rychlý R
    Epidemiol Mikrobiol Imunol; 1995 Dec; 44(4):165-8. PubMed ID: 8556244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of antibodies against hepatitis A virus among new immigrants in Israel.
    Karetnyi YV; Mendelson E; Shlyakhov E; Rubinstein E; Golubev N; Levin R; Sandler M; Schreiber M; Rubinstein U; Shif I
    J Med Virol; 1995 May; 46(1):61-5. PubMed ID: 7623008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Testing for antibody to hepatitis A to decrease the cost of hepatitis A prophylaxis with immune globulin or hepatitis A vaccines.
    Bryan JP; Nelson M
    Arch Intern Med; 1994 Mar; 154(6):663-8. PubMed ID: 8129500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High prevalence of antibody against hepatitis A virus in an institution for the mentally handicapped.
    Poovorawan Y; Theamboonlers A; Chongsrisawat V; Vimolkej T; Nantasook J
    Asian Pac J Allergy Immunol; 1997 Jun; 15(2):89-92. PubMed ID: 9346272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Routine testing for IgG antibodies against hepatitis A virus in Israel.
    Samuels N
    BMC Public Health; 2005 Jun; 5():60. PubMed ID: 15935104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiology and prevention of hepatitis A in travelers.
    Steffen R; Kane MA; Shapiro CN; Billo N; Schoellhorn KJ; van Damme P
    JAMA; 1994 Sep; 272(11):885-9. PubMed ID: 8078167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. National Advisory Committee on Immunization (NACI). Statement on the prevention of hepatitis A infections.
    Can Commun Dis Rep; 1994 Aug; 20(16):133-43. PubMed ID: 7951129
    [No Abstract]   [Full Text] [Related]  

  • 19. [Vaccination against hepatitis A].
    Giusti G; Russo M
    Recenti Prog Med; 1992 Jun; 83(6):313-20. PubMed ID: 1323136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High prevalence of hepatitis A virus antibody among Bangladeshi children and young adults warrants pre-immunization screening of antibody in HAV vaccination strategy.
    Ahmed M; Munshi SU; Nessa A; Ullah MS; Tabassum S; Islam MN
    Indian J Med Microbiol; 2009; 27(1):48-50. PubMed ID: 19172060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.